# Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

Source: https://onco.cc/trials/nct06510374/  
OnCo record `nct06510374` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Nadofaragene firadenovec in bladder & urothelial cancer, run by Ferring Pharmaceuticals, now recruiting.

## Summary

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer is a phase 3 interventional study registered as NCT06510374 by Ferring Pharmaceuticals, with 454 participants planned, started 2024-10-01 and due to reach its primary completion in 2028-06-30. Interventions recorded: Nadofaragene Firadenovec.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06510374
- Phase: 3
- Setting: A Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
- Sponsor: Ferring Pharmaceuticals
- Enrolled: 454

## Sources

- ClinicalTrials.gov NCT06510374: https://clinicaltrials.gov/study/NCT06510374

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Nadofaragene firadenovec](https://onco.cc/drugs/nadofaragene-firadenovec/)
- companies: [Ferring Pharmaceuticals](https://onco.cc/companies/ferring/)

---
JSON: https://onco.cc/api/v1/entities/nct06510374.json